The medical community has long operated under the assumption that significant weight loss naturally precipitates an increase in physical activity, as the reduced physical burden on the joints and cardiovascular system theoretically makes movement easier. However, groundbreaking research presented at the ENDO 2026 annual meeting suggests a paradoxical trend among those utilizing glucagon-like peptide-1 (GLP-1) receptor agonists. According to a comprehensive analysis of data from the National Institutes of Health’s (NIH) "All of Us" Research Program, patients who successfully lost weight using these medications actually tended to record fewer daily steps and engage in less moderate-to-vigorous physical activity (MVPA) than they did prior to starting treatment.
The study, led by Dr. Sajana Maharjan of HSHS St. John’s Hospital in Springfield, Illinois, highlights a critical concern in the rapidly evolving landscape of obesity management. While GLP-1 medications—including semaglutide (Wegovy, Ozempic), liraglutide (Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound)—are remarkably effective at reducing total body mass, they are not selective in their targets. These drugs facilitate the loss of both adipose tissue (fat) and lean muscle mass. Without a corresponding increase in physical activity, particularly resistance and weight-bearing exercise, patients risk a decline in functional strength and long-term metabolic health.
The Paradox of Weight Loss and Reduced Mobility
The findings presented by Dr. Maharjan challenge the "automaticity" of lifestyle improvement following medical weight loss. In a retrospective pre-post cohort study, researchers analyzed the behavior of 1,950 adults with obesity who were prescribed GLP-1 medications. To ensure the accuracy of the activity data, the team focused on a subset of 753 participants who possessed consistent wearable-device data, primarily from Fitbit trackers, linked to their electronic health records (EHR).
The demographic profile of the cohort was predominantly female (78.6%), with a mean age of 52.7 years. This demographic reflects the current primary consumer base for GLP-1 weight loss treatments. By comparing each individual’s physical activity levels before the initiation of the drug therapy with their activity levels afterward, the researchers were able to isolate the behavioral changes associated with the treatment period.
The results were stark. On average, the daily step counts for participants decreased from 5,047 to 4,487 steps per day. Furthermore, the time spent in moderate-to-vigorous physical activity (MVPA) fell from 28 minutes to 22 minutes per day. Rather than becoming more active as the pounds dropped, the participants became more sedentary.
Methodology: Leveraging the NIH All of Us Research Program
The reliability of this study stems from its use of the "All of Us" Research Program, a massive longitudinal effort by the NIH to build one of the most diverse health databases in history. Unlike previous studies that relied on self-reported activity—which is notoriously subject to recall bias and overestimation—this research utilized objective data from wearable fitness trackers.
By linking Fitbit data directly to EHRs, the researchers could track real-time physiological responses and movement patterns over several months. This provided a "real-world" look at how these medications affect daily life outside of a controlled clinical trial setting. The study is the first of its scale to use wearable technology to evaluate the physical activity levels of adults specifically taking GLP-1 receptor agonists.
The analysis accounted for various confounding factors, but the downward trend in activity remained consistent. The researchers looked for evidence that weight loss might eventually trigger an "activity burst," but the data suggested that as weight went down, movement followed suit.
The Critical Risk of Lean Muscle Mass Depletion
One of the most pressing concerns raised by Dr. Maharjan is the preservation of lean muscle mass. GLP-1 receptor agonists work primarily by slowing gastric emptying and signaling the brain to induce satiety. While this leads to a reduction in caloric intake, the resulting weight loss often includes a significant percentage of muscle tissue—sometimes estimated at 20% to 40% of the total weight lost.
Muscle is a metabolically active tissue; it burns more calories at rest than fat and is essential for glucose regulation and skeletal support. When patients lose muscle mass without replacing it through exercise, they may experience "sarcopenic obesity"—a condition where an individual has a low-weight or normal-weight appearance but a high body fat percentage and weakened physical functionality.
"While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise," Maharjan stated during her presentation. "The findings in our study reinforce that exercise cannot be optional for people taking these medications. People need targeted interventions that encourage physical activity alongside medication for obesity."
Demographic Disparities and the Impact of Pre-existing Conditions
The study further identified specific subgroups that experienced more pronounced declines in activity. Interestingly, the largest decreases in daily steps and MVPA were observed in men and in individuals who reported pre-existing joint or muscle pain.
The decline in men is particularly noteworthy, as it suggests that the behavioral response to GLP-1 medications may be gender-influenced, or perhaps that baseline activity levels in men were higher and thus had a "further distance to fall." For those with joint and muscle pain, the lack of an activity increase is discouraging. Traditionally, doctors have told patients that losing weight would alleviate pressure on the knees and hips, thereby reducing pain and enabling movement. However, this study suggests that the medication itself, or the rapid nature of the weight loss, may not be enough to overcome the psychological or physiological barriers to movement in chronic pain patients.
Surprisingly, other factors such as age, a history of heart failure, or a prior stroke did not significantly alter the results. The decline was relatively uniform across these high-risk categories, indicating that the phenomenon is likely a direct result of the medication’s influence on energy levels or a lack of integrated lifestyle counseling.
The Evolution of GLP-1 Receptor Agonists: A Brief Chronology
To understand the context of this study, it is necessary to look at the rapid ascent of GLP-1 medications in modern medicine:
- 2005: The FDA approved the first GLP-1 receptor agonist, exenatide (Byetta), for the treatment of Type 2 diabetes.
- 2014: Liraglutide (Saxenda) became the first GLP-1 approved specifically for chronic weight management.
- 2017-2021: Semaglutide (Ozempic) gained FDA approval for diabetes, followed by Wegovy for weight loss. This period marked the beginning of the "GLP-1 boom," fueled by social media and celebrity endorsements.
- 2023: Tirzepatide (Zepbound), a dual-agonist (GLP-1 and GIP), was approved for weight loss, showing even greater efficacy in clinical trials.
- 2024-2026: Research shifts from proving weight loss efficacy to understanding the "quality" of weight loss and long-term maintenance, leading to Dr. Maharjan’s findings at ENDO 2026.
This timeline shows a shift from treating a metabolic disease (diabetes) to addressing a global obesity epidemic. However, the medical infrastructure for supporting these patients has not always kept pace with the prescriptions, often leaving the "lifestyle" component of "lifestyle and medication" underdeveloped.
Expert Reactions and the "Skinny Fat" Phenomenon
The results of the study have prompted reactions from across the endocrinology and fitness sectors. Many clinicians are now calling for a shift in how these drugs are prescribed. Rather than simply monitoring the scale, some experts suggest that doctors should be monitoring body composition (fat vs. muscle) and prescribing specific "exercise dosages" alongside the medication.
Dietitians and physical therapists have noted that the "fatigue" often reported as a side effect of GLP-1s—likely due to significant caloric deficits—may be a primary driver of the reduced step counts. If a patient feels lethargic because they are eating significantly less, they are less likely to take the stairs or go for a walk, creating a cycle of inactivity.
The "skinny fat" phenomenon—where a person reaches a healthy weight but lacks the muscle tone to support their metabolic health—is becoming a primary concern for long-term weight maintenance. Once a patient stops taking the medication, the lack of muscle mass means their basal metabolic rate is lower than before, making weight regain (the "yo-yo effect") almost inevitable if activity levels do not increase.
Broader Public Health Implications and Future Directions
The implications of Dr. Maharjan’s study are far-reaching for public health policy and insurance coverage. If GLP-1 medications lead to a more sedentary lifestyle, the long-term cost savings associated with weight loss (such as reduced diabetes and heart disease) might be partially offset by new issues related to frailty, falls in the elderly, and reduced cardiovascular fitness.
For healthcare providers, the message is clear: the prescription pad is only half the solution. Integrated obesity care must include:
- Resistance Training: To combat the loss of lean muscle mass.
- Nutritional Counseling: To ensure that the calories consumed are high in protein to support muscle synthesis.
- Behavioral Monitoring: Utilizing wearable technology not just for research, but as a clinical tool to encourage patients to meet activity goals.
As GLP-1 medications become even more prevalent, future research will likely focus on whether adding specific exercise programs can reverse the sedentary trend observed in this study. For now, the data serves as a vital reminder that while pharmaceutical interventions can transform a person’s weight, they do not automatically transform their habits. The "miracle" of the weight-loss shot still requires the hard work of movement to ensure that the health gains are both functional and permanent.
